Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
Abstract Background and objectives Inhibition of Abelson (Abl) tyrosine kinase as a therapeutic target has been gaining attention in neurodegeneration. Post-mortem Alzheimer’s and Parkinson’s disease brains show that the levels of several other tyrosine kinases, including Discoidin Domain Receptors...
Main Authors: | Alan J. Fowler, Michaeline Hebron, Alexander A. Missner, Ruchong Wang, Xiaokong Gao, Bahjat T. Kurd-Misto, Xiaoguang Liu, Charbel E.-H. Moussa |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-03-01
|
Series: | Drugs in R&D |
Online Access: | http://link.springer.com/article/10.1007/s40268-019-0266-z |
Similar Items
-
Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
by: Michaeline Hebron, et al.
Published: (2015-01-01) -
Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
by: Lin T, et al.
Published: (2017-04-01) -
DDR1 promotes E-cadherin stability via inhibition of Src activation-mediated E-cadherin endocytosis
by: Hong-RuChen, et al.
Published: (2012) -
CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition
by: Cynthia M. Simbulan-Rosenthal, et al.
Published: (2019-01-01) -
Abl is able to inhibit cell engulfment.
by: Richard Robinson
Published: (2009-04-01)